BioAlliance Pharma SA has entered an agreement with Penn Pharma for the manufacture of Validive, currently in a Phase II trials for the prevention and treatment of severe oral mucositis induced by radiotherapy and/or chemotherapy in head and neck cancer patients. Penn will provide pharmaceutical development of Validive, including the production of Phase III clinical batches and commercial production. Validive has been granted Fast Track designation by the FDA enabling an accelerated data review....